Insulet price target raised to $260 from $255 at Jefferies

Jefferies raised the firm’s price target on Insulet to $260 from $255 and keeps a Buy rating on the shares following the company’s “big beat” and guidance raise. Strength was broad-based geographically, says the analyst, who was “impressed by the quarter” and sees more product contributions ahead.